CN103347509A - 用于治疗癌症的化合物和组合物 - Google Patents
用于治疗癌症的化合物和组合物 Download PDFInfo
- Publication number
- CN103347509A CN103347509A CN2011800523403A CN201180052340A CN103347509A CN 103347509 A CN103347509 A CN 103347509A CN 2011800523403 A CN2011800523403 A CN 2011800523403A CN 201180052340 A CN201180052340 A CN 201180052340A CN 103347509 A CN103347509 A CN 103347509A
- Authority
- CN
- China
- Prior art keywords
- formula
- chemical compound
- alkyl
- cancer
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 Cc1cc(*)*(*)c(*)c1 Chemical compound Cc1cc(*)*(*)c(*)c1 0.000 description 2
- MOVTZAQTBFNXKK-UHFFFAOYSA-N CCCCCc(cc(CC(O)=O)cc1)c1O Chemical compound CCCCCc(cc(CC(O)=O)cc1)c1O MOVTZAQTBFNXKK-UHFFFAOYSA-N 0.000 description 1
- SQFQJIGRIQCEBA-UHFFFAOYSA-O CCCCCc(cc(CC(O[NH3+])=O)cc1)c1O Chemical compound CCCCCc(cc(CC(O[NH3+])=O)cc1)c1O SQFQJIGRIQCEBA-UHFFFAOYSA-O 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/32—Phenylacetic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
- C07C57/48—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/18—Saturated compounds containing keto groups
- C07C62/20—Saturated compounds containing keto groups with a saturated six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
浓度(μM) | CTGF抑制(%) | |
癸酸钠 | 500 | 51 |
化合物I | 200 | 54 |
化合物II | 100 | 38 |
化合物III | 500 | 46 |
化合物IV | 500 | 34 |
化合物VIII | 200 | 47 |
化合物XI | 500 | 28 |
化合物XIII | 125 | 29 |
化合物XV | 20 | 22 |
化合物XVII | 7.5 | 40 |
化合物XVIII | 200 | 49 |
化合物XIX | 63 | 45 |
Claims (30)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610353298.3A CN105997967B (zh) | 2010-10-27 | 2011-10-26 | 用于治疗癌症的化合物和组合物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40706910P | 2010-10-27 | 2010-10-27 | |
US61/407069 | 2010-10-27 | ||
US61/407,069 | 2010-10-27 | ||
PCT/CA2011/001179 WO2012097427A1 (en) | 2010-10-27 | 2011-10-26 | Compounds and compositions for the treatment of cancer |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610353298.3A Division CN105997967B (zh) | 2010-10-27 | 2011-10-26 | 用于治疗癌症的化合物和组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103347509A true CN103347509A (zh) | 2013-10-09 |
CN103347509B CN103347509B (zh) | 2016-06-08 |
Family
ID=46515034
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180052340.3A Active CN103347509B (zh) | 2010-10-27 | 2011-10-26 | 用于治疗癌症的化合物和组合物 |
CN201610353298.3A Active CN105997967B (zh) | 2010-10-27 | 2011-10-26 | 用于治疗癌症的化合物和组合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610353298.3A Active CN105997967B (zh) | 2010-10-27 | 2011-10-26 | 用于治疗癌症的化合物和组合物 |
Country Status (25)
Country | Link |
---|---|
US (2) | US9114118B2 (zh) |
EP (2) | EP3443957B1 (zh) |
JP (2) | JP6007186B2 (zh) |
KR (2) | KR101821646B1 (zh) |
CN (2) | CN103347509B (zh) |
AU (2) | AU2011356583C1 (zh) |
BR (1) | BR112013010507A2 (zh) |
CA (1) | CA2816093C (zh) |
CL (1) | CL2013001152A1 (zh) |
DK (2) | DK2632452T3 (zh) |
EA (2) | EA035494B1 (zh) |
ES (2) | ES2703257T3 (zh) |
HK (1) | HK1189836A1 (zh) |
IL (2) | IL225599A (zh) |
MX (2) | MX365807B (zh) |
MY (2) | MY162420A (zh) |
NZ (1) | NZ610851A (zh) |
PH (1) | PH12016502324A1 (zh) |
PL (2) | PL2632452T3 (zh) |
PT (2) | PT3443957T (zh) |
SG (2) | SG189538A1 (zh) |
TR (1) | TR201819987T4 (zh) |
TW (2) | TWI578983B (zh) |
WO (1) | WO2012097427A1 (zh) |
ZA (1) | ZA201303035B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106267213A (zh) * | 2015-05-27 | 2017-01-04 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP在治疗肿瘤联合用药中的应用 |
CN106999456A (zh) * | 2014-10-10 | 2017-08-01 | 普罗米蒂克医药Smt有限公司 | 用于预防和治疗骨质疏松症的被取代的芳族化合物和药物组合物 |
CN106999459A (zh) * | 2014-10-10 | 2017-08-01 | 普罗米蒂克医药Smt有限公司 | 用于预防和治疗骨质疏松症的苯基酮羧酸盐化合物和药物组合物 |
CN107106526A (zh) * | 2014-11-12 | 2017-08-29 | 普罗米蒂克医药Smt有限公司 | 用于组织自修复和再生的经取代芳族化合物和药物组合物 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3443957B1 (en) * | 2010-10-27 | 2020-11-25 | Liminal Biosciences Limited | Compounds and compositions for the treatment of cancer |
TWI742541B (zh) * | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
RU2560702C1 (ru) * | 2014-06-05 | 2015-08-20 | Общество с ограниченной ответственностью "Научно-производственный центр "Амфион" (ООО "НПЦ "Амфион") | Фармацевтическая композиция для применения в онкологии |
SG10201913998YA (en) | 2017-07-25 | 2020-03-30 | Taris Biomedical Llc | Methods of treating tumor metastasis |
CA3121830A1 (en) * | 2018-12-05 | 2020-06-11 | Liminal R&D Biosciences Inc. | Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alstrom syndrome |
US11246945B2 (en) | 2019-06-07 | 2022-02-15 | National Defense Medical Center | Cisplatin-loaded microbubbles, pharmaceutical composition for treatment of cancer, method for preparing pharmaceutical compositions and method for treating cancer |
CN114436822B (zh) * | 2022-01-12 | 2024-04-16 | 厦门稀土材料研究所 | 一枝蒿酮酸和生物碱复盐及其制备方法和用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0268907A2 (en) * | 1986-11-19 | 1988-06-01 | Carl Richard Thornfeldt | Treatment of disease conditions relating to hyperactive organelles |
US5605930A (en) * | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
CN1612729A (zh) * | 2001-11-20 | 2005-05-04 | 冬姆佩股份公司 | 2-芳基-丙酸及含有它们的药物组合物 |
WO2010127440A1 (en) * | 2009-05-04 | 2010-11-11 | Prometic Biosciences Inc. | Substituted aromatic compounds and pharmaceutical uses thereof |
WO2010127448A1 (en) * | 2009-05-04 | 2010-11-11 | Prometic Biosciences Inc. | Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1169768C (zh) * | 2002-04-26 | 2004-10-06 | 中国科学院上海有机化学研究所 | (4-炔基)-芳香酮酸类化合物、合成方法及应用 |
CA2506897A1 (en) * | 2002-12-27 | 2004-07-15 | Tibotec Bvba | Fluorogenic enzyme substrates and methods of preparation |
WO2005010202A2 (en) * | 2003-07-16 | 2005-02-03 | Ligand Pharmacueticals Incorporated | PHENYL ACETIC ACID DERIVATIVES AS HEPATOCYTE NUCLEAR FACTOR 4α (HNF-4α) MODULATOR COMPOUNDS |
WO2005009104A2 (en) * | 2003-07-16 | 2005-02-03 | Ligand Pharmacueticals Incorporated | Benzoic and phenyl acetic acid derivatives as hnf-4 modulators |
US8198328B2 (en) * | 2004-01-21 | 2012-06-12 | New York University | Treatment of cancer using benzoic acid derivatives |
DK2061452T3 (da) | 2006-09-01 | 2012-02-13 | Piramal Life Sciences Ltd | Anvendelse af koffeinsyre og derivater deraf mod cancer |
CN101616583A (zh) * | 2007-02-08 | 2009-12-30 | 爱密斯菲尔科技公司 | 苯烷基羧酸输送剂 |
ES2664594T3 (es) | 2007-11-02 | 2018-04-20 | Prometic Pharma Smt Limited | Ácidos grasos de cadena media y glicéridos como agentes nefroprotectores |
WO2009055932A1 (en) | 2007-11-02 | 2009-05-07 | Prometic Biosciences Inc. | Substituted phenylpropionic acids as stimulators of hematopoiesis and erythropoiesis |
CN101903028B (zh) * | 2007-12-19 | 2013-06-05 | 普罗米蒂克生物科学公司 | 与吉西他滨组合用于治疗胰腺癌的中等链长脂肪酸、盐类及三酸甘油酯 |
EP3443957B1 (en) * | 2010-10-27 | 2020-11-25 | Liminal Biosciences Limited | Compounds and compositions for the treatment of cancer |
-
2011
- 2011-10-26 EP EP18191792.3A patent/EP3443957B1/en active Active
- 2011-10-26 US US13/882,355 patent/US9114118B2/en not_active Expired - Fee Related
- 2011-10-26 DK DK11856486.3T patent/DK2632452T3/en active
- 2011-10-26 MY MYPI2013001522A patent/MY162420A/en unknown
- 2011-10-26 TW TW100138943A patent/TWI578983B/zh not_active IP Right Cessation
- 2011-10-26 MX MX2013004832A patent/MX365807B/es active IP Right Grant
- 2011-10-26 NZ NZ610851A patent/NZ610851A/en unknown
- 2011-10-26 CA CA2816093A patent/CA2816093C/en active Active
- 2011-10-26 CN CN201180052340.3A patent/CN103347509B/zh active Active
- 2011-10-26 BR BR112013010507A patent/BR112013010507A2/pt not_active Application Discontinuation
- 2011-10-26 PL PL11856486T patent/PL2632452T3/pl unknown
- 2011-10-26 TW TW106101424A patent/TWI620563B/zh not_active IP Right Cessation
- 2011-10-26 ES ES11856486T patent/ES2703257T3/es active Active
- 2011-10-26 JP JP2013535215A patent/JP6007186B2/ja not_active Expired - Fee Related
- 2011-10-26 SG SG2013032354A patent/SG189538A1/en unknown
- 2011-10-26 CN CN201610353298.3A patent/CN105997967B/zh active Active
- 2011-10-26 EP EP11856486.3A patent/EP2632452B1/en active Active
- 2011-10-26 TR TR2018/19987T patent/TR201819987T4/tr unknown
- 2011-10-26 SG SG10201807622WA patent/SG10201807622WA/en unknown
- 2011-10-26 PT PT181917923T patent/PT3443957T/pt unknown
- 2011-10-26 EA EA201791585A patent/EA035494B1/ru not_active IP Right Cessation
- 2011-10-26 AU AU2011356583A patent/AU2011356583C1/en not_active Ceased
- 2011-10-26 PL PL18191792T patent/PL3443957T3/pl unknown
- 2011-10-26 ES ES18191792T patent/ES2837599T3/es active Active
- 2011-10-26 MY MYPI2017000606A patent/MY184343A/en unknown
- 2011-10-26 DK DK18191792.3T patent/DK3443957T3/da active
- 2011-10-26 KR KR1020137013238A patent/KR101821646B1/ko active IP Right Grant
- 2011-10-26 EA EA201370103A patent/EA030038B1/ru not_active IP Right Cessation
- 2011-10-26 KR KR1020187001526A patent/KR101943280B1/ko active IP Right Grant
- 2011-10-26 PT PT11856486T patent/PT2632452T/pt unknown
- 2011-10-26 WO PCT/CA2011/001179 patent/WO2012097427A1/en active Application Filing
-
2013
- 2013-04-07 IL IL225599A patent/IL225599A/en active IP Right Grant
- 2013-04-25 ZA ZA2013/03035A patent/ZA201303035B/en unknown
- 2013-04-26 CL CL2013001152A patent/CL2013001152A1/es unknown
- 2013-04-26 MX MX2019007010A patent/MX2019007010A/es unknown
-
2014
- 2014-04-01 HK HK14103126.5A patent/HK1189836A1/zh not_active IP Right Cessation
-
2015
- 2015-07-13 US US14/797,957 patent/US9439882B2/en active Active
-
2016
- 2016-03-10 AU AU2016201556A patent/AU2016201556B2/en not_active Ceased
- 2016-08-04 JP JP2016153378A patent/JP6371344B2/ja not_active Expired - Fee Related
- 2016-11-22 PH PH12016502324A patent/PH12016502324A1/en unknown
-
2017
- 2017-03-10 IL IL251083A patent/IL251083B/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0268907A2 (en) * | 1986-11-19 | 1988-06-01 | Carl Richard Thornfeldt | Treatment of disease conditions relating to hyperactive organelles |
US5605930A (en) * | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
CN1612729A (zh) * | 2001-11-20 | 2005-05-04 | 冬姆佩股份公司 | 2-芳基-丙酸及含有它们的药物组合物 |
WO2010127440A1 (en) * | 2009-05-04 | 2010-11-11 | Prometic Biosciences Inc. | Substituted aromatic compounds and pharmaceutical uses thereof |
WO2010127448A1 (en) * | 2009-05-04 | 2010-11-11 | Prometic Biosciences Inc. | Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof |
Non-Patent Citations (2)
Title |
---|
ALESSIO MORICONI, ET AL: "Design of Noncompetitive Interleukin-8 Inhibitors Acting on CXCR1 and CXCR2", 《J. MED. CHEM.》, 31 December 2007 (2007-12-31), pages 3984 - 4002, XP002607876, DOI: 10.1021/JM061469T * |
W. J. P. NEISH: "Phenylacetic Acid as a Potential Therapeutic Agent for the Treatment of Human Cancer", 《DEPARTMENT OF PHARMACOLOGY AND THERAPEUTICS》, vol. 127, no. 7, 14 August 1970 (1970-08-14), pages 860 - 861 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106999456A (zh) * | 2014-10-10 | 2017-08-01 | 普罗米蒂克医药Smt有限公司 | 用于预防和治疗骨质疏松症的被取代的芳族化合物和药物组合物 |
CN106999459A (zh) * | 2014-10-10 | 2017-08-01 | 普罗米蒂克医药Smt有限公司 | 用于预防和治疗骨质疏松症的苯基酮羧酸盐化合物和药物组合物 |
CN106999459B (zh) * | 2014-10-10 | 2020-07-10 | 里米诺生物科学有限公司 | 用于预防和治疗骨质疏松症的苯基酮羧酸盐化合物和药物组合物 |
CN106999456B (zh) * | 2014-10-10 | 2020-07-10 | 里米诺生物科学有限公司 | 用于预防和治疗骨质疏松症的被取代的芳族化合物和药物组合物 |
CN107106526A (zh) * | 2014-11-12 | 2017-08-29 | 普罗米蒂克医药Smt有限公司 | 用于组织自修复和再生的经取代芳族化合物和药物组合物 |
CN107106526B (zh) * | 2014-11-12 | 2021-05-28 | 普罗米蒂克医药Smt有限公司 | 用于组织自修复和再生的经取代芳族化合物和药物组合物 |
CN106267213A (zh) * | 2015-05-27 | 2017-01-04 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP在治疗肿瘤联合用药中的应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103347509B (zh) | 用于治疗癌症的化合物和组合物 | |
CN101119747A (zh) | 组织因子产生抑制剂 | |
TW201620887A (zh) | 化合物及方法 | |
TWI580670B (zh) | 作爲鱗狀癌及肝癌抑制劑的類化合物及其用途 | |
CN103483275A (zh) | Nsaid类抗炎止痛药物和egfr激酶抑制剂的偶联化合物及其合成方法和应用 | |
WO2022089612A1 (zh) | 尿苷衍生物在制备药物中的应用 | |
CN101098859A (zh) | 嘧啶酮类化合物及其制备和用途 | |
CN110049768B (zh) | 酚噻嗪衍生物及其使用方法 | |
CN109384689A (zh) | 含氰基乙烯连接链的考布他汀a4类似物及其在制备抗肿瘤药物中的应用 | |
CN107001258A (zh) | 作为用于治疗癌症的治疗剂的4‑氧代‑n‑(4‑羟基苯基)视黄酰胺衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1189836 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160727 Address after: cambridge Patentee after: The general Midike Pharmaceutical Co. Ltd. SMT Address before: Quebec Patentee before: Prometic Biosciences Inc. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1189836 Country of ref document: HK |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Compound and composition for treatment of cancer Effective date of registration: 20181016 Granted publication date: 20160608 Pledgee: Structured Alfa limited partnership Pledgor: The general Midike Pharmaceutical Co. Ltd. SMT Registration number: 2018990000969 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |